Keywords: licenses, neopharm, drugs, 65m, deal, pharmaceuticals, licensed
P&U licenses NeoPharm drugs in $65M deal
Article | 25 February 1999
NeoPharm Pharmaceuticals has licensed development and commercializationrights to two of its anticancer products - liposome-encapsulated paclitaxel (LEP) and liposome-encapsulated doxorubicin ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
